Skip to main content
. 2019 Feb;9(1):53–63. doi: 10.1212/CPJ.0000000000000567

Table.

Overview of the disease-modifying therapies in RMS

graphic file with name NEURCLINPRACT2017023382TT1.jpg

graphic file with name NEURCLINPRACT2017023382TT1A.jpg

graphic file with name NEURCLINPRACT2017023382TT1B.jpg

graphic file with name NEURCLINPRACT2017023382TT1C.jpg